Kyverna Therapeutics, Inc. (KYTX)
7.66
-0.19
(-2.42%)
USD |
NASDAQ |
Jun 10, 16:00
7.645
-0.02
(-0.20%)
After-Hours: 20:00
Kyverna Therapeutics Enterprise Value : 260.99M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 260.99M |
| June 09, 2026 | 272.49M |
| June 08, 2026 | 264.01M |
| June 05, 2026 | 249.49M |
| June 04, 2026 | 278.54M |
| June 03, 2026 | 270.67M |
| June 02, 2026 | 275.52M |
| June 01, 2026 | 294.89M |
| May 29, 2026 | 313.05M |
| May 28, 2026 | 320.92M |
| May 27, 2026 | 319.54M |
| May 26, 2026 | 320.76M |
| May 22, 2026 | 324.40M |
| May 21, 2026 | 338.39M |
| May 20, 2026 | 318.32M |
| May 19, 2026 | 326.23M |
| May 18, 2026 | 316.50M |
| May 15, 2026 | 374.26M |
| May 14, 2026 | 450.25M |
| May 13, 2026 | 452.68M |
| May 12, 2026 | 419.24M |
| May 11, 2026 | 425.93M |
| May 08, 2026 | 365.74M |
| May 07, 2026 | 362.70M |
| May 06, 2026 | 373.04M |
| Date | Value |
|---|---|
| May 05, 2026 | 357.23M |
| May 04, 2026 | 344.47M |
| May 01, 2026 | 336.56M |
| April 30, 2026 | 330.00M |
| April 29, 2026 | 305.78M |
| April 28, 2026 | 323.94M |
| April 27, 2026 | 341.50M |
| April 24, 2026 | 345.73M |
| April 23, 2026 | 339.07M |
| April 22, 2026 | 416.56M |
| April 21, 2026 | 385.08M |
| April 20, 2026 | 478.30M |
| April 17, 2026 | 398.40M |
| April 16, 2026 | 374.18M |
| April 15, 2026 | 366.31M |
| April 14, 2026 | 363.89M |
| April 13, 2026 | 371.76M |
| April 10, 2026 | 339.07M |
| April 09, 2026 | 377.21M |
| April 08, 2026 | 355.42M |
| April 07, 2026 | 362.08M |
| April 06, 2026 | 340.89M |
| April 02, 2026 | 334.23M |
| April 01, 2026 | 328.18M |
| March 31, 2026 | 319.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| X4 Pharmaceuticals, Inc. | 195.35M |
| Arrowhead Pharmaceuticals, Inc. | 9.517B |
| Oncolytics Biotech, Inc. | 87.93M |
| Sangamo Therapeutics, Inc. | 53.47M |
| Sarepta Therapeutics, Inc. | 1.979B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -39.73M |
| Total Expenses (Quarterly) | 39.73M |
| EPS Diluted (Quarterly) | -0.6574 |
| Earnings Yield | -42.82% |
| Normalized Earnings Yield | -42.82 |